Deciphering cross-resistance mechanisms associated to targeted therapies and immunotherapy in BRAFmutmelanoma: The role of tumor-associated macrophages and galectin-1
; Mahmoud, Yamil Damián ; Merlo, Joaquín Pedro ; Manselle Cocco, Montana Nicolle ; Massaro, Mora ; Gatto, Sabrina Gisela ; Morales, Rosa María ; Girotti, Maria Romina ; Pérez Sáez, Juan Manuel ; Rabinovich, Gabriel Adrián Otros responsables
Fecha
2023
Editorial
American Association for Cancer Research
Revista
Título del libro
Nombre del evento
AACR Annual Meeting 2023: Advancing the frontiers of cancer science and medicine
Fecha del evento
2023-04-14
Institución organizadora
American Association for Cancer Research
ISSN
0008-5472
eISSN
1538-7445
ISBN
Idioma
Inglés
Tipo del evento
Reunión
Clasificación temática
Palabras clave
Resumen
Both targeted therapies (TT) and immunotherapies have revolutionized the treatment of metastatic melanoma patients. Particularly, TT with BRAFi or BRAFi/MEKi leads to prompt but not durable responses in most patients due to the development of resistance within 1 year. Tumors refractory to TT derive little benefit from subsequent immunotherapy. Here we aim to elucidate how previous treatments with TT shape tumor-immune landscape and how it could be overcome therapeutically.
Colecciones
Aprobación
Revisión
Complementado por
Referenciado por
Licencia Creative Commons
Excepto donde se indique lo contrario, la licencia de este ítem se describe como by-nc-sa
Identificadores
Deciphering cross-resistance mechanisms associated to targeted therapies and immunotherapy in BRAFmutmelanoma: The role of tumor-associated macrophages and galectin-1; AACR Annual Meeting 2023: Advancing the frontiers of cancer science and medicine; Orlando; Estados Unidos; 2023; 2261-2261
Altmétricas